Medicine guide

Doxazosin

8 mg · Tablet

Prescription only
alpha-Adrenergic Blocker

Active substance: Doxazosin
Used in: Heart, blood pressure and circulation
Made by: Golden State Medical Supply, Inc.
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-06-23

What it is

alpha-Adrenergic Blocker

Used for

Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension

The label’s usual adult dose

For the treatment of BPH: Initiate therapy at 1 mg once daily.

The maximum recommended dose for BPH is 8 mg once daily.

Full directions ↓

Do not take it if

The use of doxazosin is contraindicated in patients with a hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any of its components.

All warnings ↓

Good to know

Prescription only
Mediclarum could not reach the FDA to check for recalls just now. This is not a result.

74other products contain Doxazosin — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Doxazosin is an alpha 1 adrenergic antagonist indicated for:

Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension
1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH.
1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
Many patients will require more than one drug to achieve blood pressure goals.
For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.
The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).
These considerations may guide selection of therapy.
Doxazosin may be used alone or in combination with other antihypertensives.

From the official label · 2026-06-23 · DailyMed

How it works

From this product’s own US prescribing label.

Benign Prostatic Hyperplasia (BPH) The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic).
The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma.

Peak level after2–3 h

Half-life22 h

Mostly cleared after≈ 5 daysfive half-lives — our arithmetic

The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

How the body breaks it down

Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.

How it leaves the body

In a study of two subjects administered radiolabelled doxazosin 2 mg orally and 1 mg intravenously on two separate occasions, approximately 63% of the dose was eliminated in the feces and 9% of the dose was found in the urine.

With food

The effect of food on the pharmacokinetics of doxazosin was examined in a crossover study with twelve hypertensive subjects.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-23

Do not take it if

The use of doxazosin is contraindicated in patients with a hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any of its components.
Hypersensitivity to doxazosin, other quinazolines, or any other ingredient in doxazosin tablets.
( 4 )

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

For the treatment of BPH: Initiate therapy at 1 mg once daily.
Dose maybe titrated at 1 to 2-week intervals, up to 8 mg once daily.
( 2.2 ) For the treatment hypertension: Initiate therapy at 1 mg once daily.
Dose may be titrated as needed, up to 16 mg once daily.
( 2.3 )
2.1 Dosing Information Following the initial dose and with each dose increase of doxazosin, monitor blood pressure for at least 6 hours following administration.
If doxazosin administration is discontinued for several days, therapy should be restarted using the initial dosing regimen.
2.2 Benign Prostatic Hyperplasia The recommended initial dosage of doxazosin is 1 mg given once daily either in the morning or evening.
Depending on the individual patient's urodynamics and BPH symptomatology, the dose may be titrated at 1 to 2 week intervals to 2 mg, and thereafter to 4 mg and 8 mg once daily.
The maximum recommended dose for BPH is 8 mg once daily.
Routinely monitor blood pressure in these patients.
2.3 Hypertension The initial dosage of doxazosin is 1 mg given once daily.
Daily dosage may be doubled up 16 mg once daily, as needed, to achieve the desired reduction in blood pressure.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Postural hypotension with or without syncope may occur.
( 5.1 ) Risk of Intraoperative Floppy Iris Syndrome during cataract surgery.
( 5.2 ) Screen for the presence of prostate cancer prior to treatment for BPH and at regular intervals afterwards.
( 5.3 )
5.1 Postural Hypotension Postural hypotension with or without symptoms (e.g., dizziness) may develop within a few hours following administration of doxazosin.
However, infrequently, symptomatic postural hypotension has also been reported later than a few hours after dosing.
As with other alpha-blockers, there is a potential for syncope, especially after the initial dose or after an increase in dosage strength.
Advise patient how to
avoid symptoms resulting from postural hypotension and what measures to take should they develop.
Concomitant administration of doxazosin with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension.
5.2 Cataract Surgery Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients on or previously treated with alpha 1 blockers.
This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions.
The patient's surgeon should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.
There does not appear to be a benefit of stopping alpha 1 blocker therapy prior to cataract surgery.
5.3 Prostate Cancer Carcinoma of the prostate causes many of the symptoms associated with BPH and the two disorders frequently co-exist.
Carcinoma of the prostate should therefore be ruled out prior to commencing therapy with doxazosin for the treatment of BPH.
5.4 Priapism Alpha 1 antagonists, including doxazosin, have been associated with priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation).
This condition can lead to permanent impotence if not promptly treated.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Risk Summary The limited available data with doxazosin in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.
However, untreated hypertension during pregnancy can result in increased maternal risks [see Clinical Considerations].
In animal reproduction studies, no adverse developmental effects were observed when doxazosin was orally administered to pregnant rabbits and rats during the period of organogenesis at doses of up to 41 and 20 mg/kg, respectively (exposures in rabbits and rats were 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose).
A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival [see Data].
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).
Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.
Data Animal Data Radioactivity was found to cross the placenta following oral administration of labelled doxazosin to pregnant rats.
Studies in pregnant rabbits and rats at daily oral doses of up to 41 and 20 mg/kg, respectively (plasma drug concentrations of 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose), have revealed no evidence of adverse developmental effects.
A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival.
In peri- and postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin (about 8 times human AUC exposure with a 12 mg/day therapeutic dose) was delayed, as evidenced by slower body weight gain and slightly later appearance of anatomical features and reflexes.
IN SPECIFIC POPULATIONS Hepatic Impairment: Monitor for hypotension.
( 8.6 , 12.3 )
8.1 Pregnancy Risk Summary The limited available data with doxazosin in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.
However, untreated hypertension during pregnancy can result in increased maternal risks [see Clinical Considerations].
In animal reproduction studies, no adverse developmental effects were observed when doxazosin was orally administered to pregnant rabbits and rats during the period of organogenesis at doses of up to 41 and 20 mg/kg, respectively (exposures in rabbits and rats were 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose).
A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival [see Data].
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).
Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.
Data Animal Data Radioactivity was found to cross the placenta following oral administration of labelled doxazosin to pregnant rats.
Studies in pregnant rabbits and rats at daily oral doses of up to 41 and 20 mg/kg, respectively (plasma drug concentrations of 10 and 4 times, respectively, the human AUC exposures with a 12 mg/day therapeutic dose), have revealed no evidence of adverse developmental effects.
A dosage regimen of 82 mg/kg/day in the rabbit was associated with reduced fetal survival.
In peri- and postnatal studies in rats, postnatal development at maternal doses of 40 or 50 mg/kg/day of doxazosin (about 8 times human AUC exposure with a 12 mg/day therapeutic dose) was delayed, as evidenced by slower body weight gain and slightly later appearance of anatomical features and reflexes.
8.2 Lactation Risk Summary There is limited information on the presence of doxazosin in human milk [see Data].
There is no information on the effects of doxazosin on the breastfeed infant or the effects on milk production.
Data A single case study reports that doxazosin is present in human milk, which resulted in an infant dose of less than 1% of the maternal weight-adjusted dosage and a milk/plasma ratio of 0.1.
However, these data are insufficient to confirm the presence of doxazosin in human milk.
8.4 Pediatric Use The safety and effectiveness of doxazosin have not been established in children.
8.5 Geriatric Use Benign Prostatic Hyperplasia (BPH) The safety and effectiveness profile of doxazosin was similar in the elderly (age ≥ 65 years) and younger (age < 65 years) patients.
Hypertension Clinical studies of doxazosin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
8.6 Hepatic Impairment Doxazosin is extensively metabolized in the liver.
Hepatic impairment is expected to increase exposure to doxazosin.
Use of doxazosin in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended.
Monitor blood pressure and for symptoms of hypotension in patients with lesser degrees of hepatic impairment (Child-Pugh Class A and B) [see Clinical Pharmacology ( 12.3 )].

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension ( 7.1 ) Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension.
( 7.2 )
7.1 CYP 3A Inhibitors In vitro studies suggest that doxazosin is a substrate of CYP 3A4.
Strong CYP3A inhibitors may increase exposure to doxazosin.
Monitor blood pressure and for symptoms of hypotension when doxazosin is used concomitantly with strong CYP3A inhibitors [see Clinical Pharmacology ( 12.3 )].
7.2 Phosphodiesterase-5 (PDE-5) Inhibitors Concomitant administration of doxazosin with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension.
Monitor blood pressure and for symptoms of hypotension [see Warnings and Precautions ( 5.1 )].

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Experience with doxazosin overdosage is limited.
Two adolescents, who each intentionally ingested 40 mg doxazosin with diclofenac or acetaminophen, were treated with gastric lavage with activated charcoal and made full recoveries.
A two-year-old child who accidently ingested doxazosin tablets 4 mg was treated with gastric lavage and remained normotensive during the five-hour emergency room observation period.
A six-month-old child accidentally received a crushed 1 mg tablet of doxazosin and was reported to have been drowsy.
A 32-year-old female with chronic renal failure, epilepsy, and depression intentionally ingested 60 mg doxazosin (blood level = 0.9 mcg/mL; normal values in hypertensives = 0.02 mcg/mL); death was attributed to a grand mal seizure resulting from hypotension.
A 39-year-old female who ingested 70 mg doxazosin, alcohol, and Dalmane ® (flurazepam) developed hypotension which responded to fluid therapy.
The oral LD 50 of doxazosin is greater than 1,000 mg/kg in mice and rats.
The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of fluid.
As doxazosin is highly protein bound, dialysis would not be indicated.

Quoted from the official label, section “Overdosage”.

Use in children

The safety and effectiveness of doxazosin have not been established in children.

Quoted from the official label, section “Pediatric Use”.

Use in older people

Benign Prostatic Hyperplasia (BPH) The safety and effectiveness profile of doxazosin was similar in the elderly (age ≥ 65 years) and younger (age < 65 years) patients.
Hypertension Clinical studies of doxazosin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Quoted from the official label, section “Geriatric Use”.

Side effects

The most commonly reported adverse reactions from clinical trials are fatigue, malaise, hypotension, and dizziness.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Benign Prostatic Hyperplasia (BPH) The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients.
The incidence rates presented below (Table 2) are based on combined data from seven placebo-controlled trials involving once-daily administration of doxazosin in doses of 1 to 16 mg in hypertensives and 0.5 to 8 mg in normotensives.
Adverse reactions occurring more than 1% more frequently in BPH patients treated with doxazosin vs placebo are summarized in Table 1.
Table 1.
Adverse Reactions Occurring more than 1% More Frequently in BPH Patients Treated with Doxazosin Versus Placebo BODY SYSTEM Doxazosin N = 665 Placebo N = 300 NERVOUS SYSTEM DISORDERS Dizziness Includes vertigo 15.6% 9.0% Somnolence 3.0% 1.0% CARDIAC DISORDERS Hypotension 1.7% 0% RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Dyspnoea 2.6% 0.3% GASTROINTESTINAL DISORDERS Dry Mouth 1.4% 0.3% GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Fatigue 8.0% 1.7% Oedema 2.7% 0.7% Other adverse reactions occurring less than 1% more frequently in BPH patients treated with doxazosin vs placebo but plausibly related to doxazosin include:
palpitations.
Hypertension Doxazosin has been administered to approximately 4,000 hypertensive patients in clinical trials, of whom 1,679 were included in the hypertension clinical development program.
In placebo-controlled studies, adverse events occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group.
Adverse reactions occurring more than 1% more frequently in hypertensive patients treated with doxazosin vs placebo are summarized in Table 1.
Postural effects and edema appeared to be dose-related.
The prevalence rates presented below are based on combined data from placebo-controlled studies involving once-daily administration of doxazosin at doses ranging from 1 to 16 mg.
Table 2.
Adverse Reactions Occurring more than 1% More Frequently in Hypertensive Patients Treated with Doxazosin Versus Placebo BODY SYSTEM Doxazosin N = 339 Placebo N = 336 NERVOUS SYSTEM DISORDERS Dizziness 19% 9% Somnolence 5% 1% RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Rhinitis 3% 1% RENAL AND URINARY DISORDERS Polyuria 2% 0% REPRODUCTIVE SYSTEM AND BREAST DISORDERS GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Fatigue / Malaise 12% 6% Other adverse reactions occurring less than 1% more frequently in hypertensive patients treated with doxazosin vs placebo but plausibly related to doxazosin use include vertigo, hypotension, hot flushes, epistaxis and oedema.
Doxazosin has been associated with decreases in white blood cell counts.
Laboratory Changes Observed in Clinical Studies Leukopenia/Neutropenia:
Decreases in mean white blood cell (WBC) and mean neutrophil count were observed in controlled clinical trials of hypertensive patients receiving doxazosin.
In cases where follow-up was available, WBC and neutrophil counts returned to normal after discontinuation of doxazosin.
No patients became symptomatic as a result of the low WBC or neutrophil counts.
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of doxazosin.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In post-marketing experience, the following additional adverse reactions have been reported:
Blood and Lymphatic System Disorders:
leukopenia, thrombocytopenia;
Immune System Disorders: allergic reaction;
Nervous System Disorders: hypoesthesia;
Eye Disorders:
Intraoperative Floppy Iris Syndrome [see Warnings and precautions ( 5.4 )];
Cardiac Disorders: bradycardia;
Respiratory, Thoracic and Mediastinal Disorders: bronchospasm aggravated;
Gastrointestinal Disorders: vomiting;
Hepatobiliary Disorders: cholestasis, hepatitis cholestatic;
Skin and Subcutaneous Tissue Disorders: urticaria;
Musculoskeletal and Connective Tissue Disorders: muscle cramps, muscle weakness;
Renal and Urinary Disorders:
hematuria, micturition disorder, micturition frequency, nocturia;
Reproductive System and Breast Disorders: gynecomastia, priapism.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

Advise the patient to read the FDA-approved patient labeling (Patient Information).
Postural Hypotension Advise patients of the possibility of syncopal and orthostatic symptoms, especially at the initiation of therapy, and urged to
avoid driving or hazardous tasks for 24 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed.
Advise patients to report symptoms to their healthcare provider.
Priapism Advise patients of the possibility of priapism and to seek immediate medical attention
if symptoms occur.
Dispense with Patient Information available at:
www.avetpharma.com/product Distributed by:
Avet Pharmaceuticals Inc.
East Brunswick, NJ 08816 1.866.901.DRUG (3784) Revised: 05/2024 Marketed by: GSMS, Inc.
Camarillo, CA 93012 USA logo

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

FORMS AND STRENGTHS 1 mg:
Each round, white tablet, debossed "HP" above and "92" below the score on one side and plain on the other side, contains doxazosin mesylate equivalent to 1 mg doxazosin (free base). 2 mg:
Each round, yellow tablet, debossed "HP" above and "93" below the score on one side and plain on the other side, contains doxazosin mesylate equivalent to 2 mg doxazosin (free base). 4 mg:
Each round, orange tablet, debossed "HP" above and "94" below the score on one side and plain on the other side, contains doxazosin mesylate equivalent to 4 mg doxazosin (free base). 8 mg:
Each round, green tablet, debossed "HP" above and "95" below the score on one side and plain on the other side, contains doxazosin mesylate equivalent to 8 mg doxazosin (free base).
Tablets: 1 mg, 2 mg, 4 mg, 8 mg.

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

Doxazosin Tablets, USP are available as tablets for oral administration.
Each tablet contains doxazosin mesylate equivalent to 1 mg (white), 2 mg (yellow), 4 mg (orange) or 8 mg (green) of doxazosin as the free base.
The 1 mg are available as round, white tablet, debossed "HP" above and "92" below the score on one side and plain on the other side.
They are available as follows:
Bottle of 100:
1 mg (NDC 84677-044-01) The 2 mg are available as round, yellow tablet, debossed "HP" above and "93" below the score on one side and plain on the other side.
They are available as follows:
Bottle of 100:
2 mg (NDC 84677-045-01) The 4 mg are available as round, orange tablet, debossed "HP" above and "94" below the score on one side and plain on the other side.
They are available as follows:
Bottle of 100:
4 mg (NDC 84677-046-01) The 8 mg are available as round, green tablet, debossed "HP" above and "95" below the score on one side and plain on the other side.
They are available as follows:
Bottle of 100:
8 mg (NDC 84677-047-01)
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Dispense in a tight container as defined in the USP using a child-resistant closure.
KEEP THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN.

Quoted from the official label, section “How Supplied”.

What is in it

Doxazosin mesylate is a quinazoline compound that is a selective inhibitor of the alpha 1 subtype of alpha-adrenergic receptors. The chemical name of doxazosin mesylate is l-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(l,4-benzodioxan-2-ylcarbonyl) piperazine monomethanesulfonate. The empirical formula for doxazosin mesylate is C 23 H 25 N 5 O 5
CH 4 O 3 S and the molecular weight is 547.6. It has the following structure:
Doxazosin mesylate is freely soluble in dimethylsulfoxide, soluble in dimethylformamide, slightly soluble in methanol, ethanol, and water (0.8% at 25°C), and very slightly soluble in acetone and methylene chloride. Doxazosin tablets, USP for oral administration are available as colored tablets for oral use and contains doxazosin mesylate equivalent to 1 mg (white), 2 mg (yellow), 4 mg (orange) and 8 mg (green) of doxazosin as the free base. In addition, each tablet also contains the following inactive ingredients:
lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate and sodium starch glycolate. The 2 mg tablets also contain D&C Yellow No. 10 Aluminum Lake and FD&C Yellow No. 6 Aluminum Lake, the 4 mg tablets contain FD&C Yellow No. 6 Aluminum Lake, and the 8 mg tablets contain D&C Yellow No. 10 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake. structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Lactoselactose monohydrateMilk sugar: matters with lactose intolerance or a milk allergy.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (21)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 21 of 21

Details

Made by	Golden State Medical Supply, Inc.
Active substance	Doxazosin
Used in	Heart, blood pressure and circulation
Strength	8 mg
Form	Tablet
Route	Oral
Packs	100 TABLET in 1 BOTTLE
NDC	84677-047

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

81 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Tablet81 products
- 1 mg17
  1 mg · 17 companies
  +9 more
- 2 mg25
  2 mg · 25 companies
  +17 more
- 4 mg24
  4 mg · 24 companies
  +16 more
- 8 mg15
  8 mg · 15 companies
  - A-S Medication Solutions
  - Accord Healthcare Inc.
  - Aphena Pharma Solutions - Tennessee, LLC
  - Apotex Corp.
  - Aurobindo Pharma Limited
  - AvKARE
  - AvPAK
  - Golden State Medical Supply, Inc. · this page
  +7 more

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Cardura2 mgPrescription onlyTablet ROERIG · Doxazosin Cardura4 mgPrescription onlyTablet ROERIG · Doxazosin Cardura8 mgPrescription onlyTablet ROERIG · Doxazosin Cardura1 mgPrescription onlyTablet Viatris Specialty LLC · Doxazosin Cardura2 mgPrescription onlyTablet Viatris Specialty LLC · Doxazosin Cardura4 mgPrescription onlyTablet Viatris Specialty LLC · Doxazosin

See every product with Doxazosin